[google-translator]

TANDEM MS: MS/MS BLOOD SPOT CONTROLS

Disorder: Metabolic

Conditions: Amino Acid, Organic Acid, and Fatty Acid Oxidation Disorders

Biomarkers: Amino Acids, Succinylacetone, Free Carnitine, Acylcarnitines, Carnitines

PRODUCT HIGHLIGHTS

Allows for supplementary confirmation of screening performance – Third party, independent controls
Flexibility for use in any laboratory – Use is independent of screening method, vendor, or mass spectrometry system; effective for derivatized or non-derivatized test methods
Represents metabolic disease states for multiple analytes on the same card – Optimized metabolic profiles consistent with a true positive algorithm  
Monitoring biomarker ratios provides additional opportunity for quality control – Provides insight into system performance  
Option to customize analyte profile based on your laboratory’s needs Contact us for details

The SPOTCHECK® MS/MS Blood Spot Controls consist of quality control material intended for use with quantitative tandem mass spectrometry (MS/MS) systems screening for a comprehensive panel of neonatal genetic and metabolic disorders in dried human whole blood. Measurement profiles of specimen concentrations of amino acids, free carnitine, acylcarnitines, and succinylacetone (SUAC) are used in the diagnosis and treatment of organic acid, fatty acid oxidation, and amino acid disorders. The controls’ analyte profiles are designed to provide the user with a reference for quality control monitoring of system performance. The dried blood spot controls are treated in the same manner as the patient samples in the course of analysis.

ORDERING INFORMATION

PART NO.PRODUCT NAMEDESCRIPTION
82-0200P6KMS/MS Blood Spot ControlsControls with varying levels of enrichment

AMINO ACIDS

ANALYTES
Ala
Arg
Cit
Gly
Leu
Met
Orn
Phe
Tyr
Val

SUAC

ANALYTE
SUAC

ACYLCARNITINES

ANALYTES
C0
C2
C3
C4
C5
C6
C8
C3DC
C10
C5DC
C12
C14
C5OH
C16OH
C18
C5:1
C14:1
C16

ANALYTE RATIOS

ANALYTES
Val/Phe
Leu/Phe
Phe/Tyr
Cit/Arg
C0/(C16+C18)
C3/C2

DOWNLOAD OUR BROCHURE